MedTrace Logo

Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

NCT00837707 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-02-05

No results posted yet for this study

Summary

The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

Conditions

  • Dyskinesia, Drug-Induced

Interventions

DRUG

aripiprazole

Flexible dose: 5-30 mg/day

Sponsors & Collaborators

  • Department of Health

    collaborator AMBIG

  • Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan

    lead OTHER_GOV

Principal Investigators

  • Chia-Hsiang Chan, M.D. · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-08-31
Completion
2010-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837707 on ClinicalTrials.gov